A homologous-targeting cGAS-STING agonist multimodally activates dendritic cells for enhanced cancer immunotherapy
Source abstract
Abstract
Herein, we developed a doxorubicin (Dox)-loaded and 4T1 cancer cell membrane-modified hydrogenated manganese oxide nanoparticles (mHMnO-Dox) to elicit systemic antitumor immune responses. The results revealed that mHMnO-Dox actively recognized tumor cells and then effectively delivered Dox into the cells. Upon entering tumor cells, the mHMnO-Dox underwent rapid degradation and abundant release of Mn2+ and chemotherapeutic drugs. The released Mn2+ not only catalysed a Fenton-type reaction to produce excessive reactive oxygen species (ROS) but also activated the cGAS-STING pathway to boost dendritic cell (DC) maturation. This process increased cytotoxic T lymphocyte infiltration as well as natural killer cell recruitment into the tumor site. In addition, the released Dox could contribute to a chemotherapeutic effect, while activating DC cells and subsequently intensifying immune responses through immunogenic cell death (ICD) of tumor cells. Consequently, the mHMnO-Dox suppressed the primary and distal tumor growth and inhibited tumor relapse and metastasis, as well as prolonged the lifespan of tumor-bearing mice. Thus, the mHMnO-Dox multimodally activated DC cells to demonstrate synergistic antitumor activity, which was mediated via the activation of the cGAS-STING signalling pathway to regulate tumor microenvironment, ICD-mediated immunotherapy and ROS-mediated CDT. These findings suggest the therapeutic potential of mHMnO-Dox in cancer immunotherapy. STATEMENT OF SIGNIFICANCE: A cancer cell membrane-camouflaged hydrogenated mesoporous manganese oxide (mHMnO) has been developed as a cGAS-STING agonist and ICD inducer. The mHMnO effectively induced abundance of ROS production in cancer cells, which caused cancer cell death and then promoted DC maturation via tumour-associated antigen presentation. Meanwhile, the mHMnO significantly activated cGAS-STING pathway to facilitate DC maturation and cytotoxic T lymphocyte infiltration as well as natural killer cell recruitment, which further enhanced tumour immune response. In addition, the combination of the mHMnO and Dox could synergistically promote tumour ICD and then multimodally induce DC maturation, achieving an enhanced CIT. Overall, this study provides a potential strategy to design novel immunologic adjuvant for enhanced CIT.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: interferon and immune responses · Toxoplasma gondii Research Studies · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. MHC-II neoantigens shape tumor immunity and response to immunotherapy10.1038/s41586-019-1671-8 ↗
2. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer10.1093/jnci/djw192 ↗
3. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-9810.1200/JCO.2011.41.0902 ↗
4. Progress and challenges of immunotherapy in triple-negative breast cancer10.1016/j.bbcan.2021.188593 ↗
5. Dying cells actively regulate adaptive immune responses10.1038/nri.2017.9 ↗
6. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
7. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation
8. Calreticulin exposure dictates the immunogenicity of cancer cell death10.1038/nm1523 ↗
9. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death10.1038/emboj.2011.497 ↗
10. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death10.1038/emboj.2009.1 ↗
11. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy10.1038/emboj.2012.2 ↗
12. The cGAS/STING pathway: a novel target for cancer therapy
13. cGAS-STING pathway in cancer biotherapy10.1186/s12943-020-01247-w ↗
14. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing10.1038/ni.3558 ↗
15. Cyclic GMP-AMP synthase is a cytosolic dna sensor that activates the type I interferon pathway10.1126/science.1232458 ↗
16. The Ca(2+) sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum10.1038/s41590-018-0287-8 ↗
17. NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists10.1126/sciimmunol.aaz2738 ↗
18. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors10.1016/j.immuni.2014.10.019 ↗
19. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation10.1172/JCI127458 ↗
20. Pharmacological modulation of the STING pathway for cancer immunotherapy10.1016/j.molmed.2019.02.007 ↗
21. STING-dependent signaling10.1038/ni.2118 ↗
22. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response10.1016/j.immuni.2018.09.016 ↗
23. A phase 2 efficacy and safety trial of ADU-S100 and pembrolizumab in adults with head and neck cancer
24. Acetalated dextran microparticles for codelivery of STING and TLR7/8 agonists10.1021/acs.molpharmaceut.8b00579 ↗
25. Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs10.1038/nchembio.1661 ↗
26. A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy10.1016/j.jconrel.2014.04.004 ↗
27. Manganese is essential for neuronal health10.1146/annurev-nutr-071714-034419 ↗
28. Manganese-induced parkinsonism and Parkinson's disease: shared and distinguishable features10.3390/ijerph120707519 ↗
29. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy10.1038/s41565-021-00962-9 ↗
30. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy10.1038/s41422-020-00395-4 ↗
31. Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect10.1016/j.jconrel.2021.01.036 ↗
32. Mn(2+) directly activates cGAS and structural analysis suggests Mn(2+) induces a noncanonical catalytic synthesis of 2′3′-cGAMP10.1016/j.celrep.2020.108053 ↗
33. Manganese-based nanoactivator optimizes cancer immunotherapy via enhancing innate immunity10.1021/acsnano.9b06111 ↗
34. How important is oxidative damage? Lessons from Alzheimer's disease10.1016/S0891-5849(00)00158-1 ↗
35. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized fenton reaction10.1002/anie.201510031 ↗
36. Manganese-based functional nanoplatforms: nanosynthetic construction, physiochemical property, and theranostic applicability10.1002/adfm.201907066 ↗
37. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death10.1038/s41467-019-11269-8 ↗
38. Unraveling mitochondria-targeting reactive oxygen species modulation and their implementations in cancer therapy by nanomaterials
39. Simultaneous fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy10.1002/anie.201712027 ↗
40. Activation of STING by cGAMP regulates MDSCs to suppress tumor metastasis via reversing epithelial-mesenchymal transition10.3389/fonc.2020.00896 ↗
41. Recent progress of metal-based nanomaterials with anti-tumor biological effects for enhanced cancer therapy10.1002/EXP.20220001 ↗
42. Dynamic regulation of drug biodistribution by turning tumors into decoys for biomimetic nanoplatform to enhance the chemotherapeutic efficacy of breast cancer with bone metastasis10.1002/EXP.20220124 ↗
43. Breast cancer10.1038/s41572-019-0111-2 ↗